MX2020001501A - Streptococcus australis como bioterapeuticos. - Google Patents

Streptococcus australis como bioterapeuticos.

Info

Publication number
MX2020001501A
MX2020001501A MX2020001501A MX2020001501A MX2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A MX 2020001501 A MX2020001501 A MX 2020001501A
Authority
MX
Mexico
Prior art keywords
biotherapeutics
streptococcus australis
probiotics
compositions
australis
Prior art date
Application number
MX2020001501A
Other languages
English (en)
Inventor
Zachary Desantis Todd
Wonhee Han Andrew
Dabbagh Karim
Lynn YAMAMOTO Mitsuko
Baeza Raja Bernat
Kawana Shoko
Original Assignee
Second Genome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Genome Inc filed Critical Second Genome Inc
Publication of MX2020001501A publication Critical patent/MX2020001501A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La descripción se refiere a productos bioterapéuticos vivos, probióticos, composiciones farmacéuticas que comprenden dichos probióticos, y métodos para usarlos para tratar diversas enfermedades humanas. En algunos aspectos, la descripción proporciona tales composiciones que comprenden cepas de la bacteria Streptococcus australis y sus usos en el tratamiento de enfermedades o trastornos relacionados con el metabólico.
MX2020001501A 2017-08-06 2018-08-06 Streptococcus australis como bioterapeuticos. MX2020001501A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541759P 2017-08-06 2017-08-06
PCT/US2018/045330 WO2019032432A1 (en) 2017-08-06 2018-08-06 STREPTOCOCCUS AUSTRALIS AS A BIOTHERAPEUTIC AGENT

Publications (1)

Publication Number Publication Date
MX2020001501A true MX2020001501A (es) 2020-03-24

Family

ID=65272764

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001501A MX2020001501A (es) 2017-08-06 2018-08-06 Streptococcus australis como bioterapeuticos.

Country Status (10)

Country Link
US (1) US11389487B2 (es)
EP (1) EP3662087B1 (es)
JP (1) JP2020530011A (es)
KR (1) KR20200037292A (es)
CN (1) CN111050782A (es)
AU (1) AU2018314228A1 (es)
CA (1) CA3072289A1 (es)
MX (1) MX2020001501A (es)
SG (1) SG11202001051SA (es)
WO (1) WO2019032432A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020530011A (ja) 2017-08-06 2020-10-15 セカンド ゲノム インコーポレイテッド バイオ治療薬としてのストレプトコッカス・オーストラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ａｕｓｔｒａｌｉｓ）

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4580542B2 (ja) 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
PL2808024T3 (pl) * 2009-06-19 2019-09-30 Dupont Nutrition Biosciences Aps Bifidobakterie do leczenia zastoinowej niewydolności serca
RU2013133994A (ru) * 2010-12-21 2015-01-27 Нестек С.А. Способы и композиции, применимые для контроля глюкозы в крови животных
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
BR112015018625A2 (pt) * 2013-02-04 2017-09-19 Seres Therapeutics Inc composições e métodos
AU2014232370B2 (en) * 2013-03-15 2018-11-01 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CA2986203A1 (en) 2015-05-21 2016-11-24 Yeda Research And Development Co. Ltd. Bacterial populations for promoting health
US20170172167A1 (en) 2015-07-23 2017-06-22 Medela Holding Ag Infant feed and method
JP2020530011A (ja) 2017-08-06 2020-10-15 セカンド ゲノム インコーポレイテッド バイオ治療薬としてのストレプトコッカス・オーストラリス（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ａｕｓｔｒａｌｉｓ）

Also Published As

Publication number Publication date
EP3662087B1 (en) 2022-10-05
JP2020530011A (ja) 2020-10-15
EP3662087A4 (en) 2020-09-09
KR20200037292A (ko) 2020-04-08
CA3072289A1 (en) 2019-02-14
US11389487B2 (en) 2022-07-19
EP3662087A1 (en) 2020-06-10
US20200237829A1 (en) 2020-07-30
WO2019032432A1 (en) 2019-02-14
SG11202001051SA (en) 2020-03-30
CN111050782A (zh) 2020-04-21
AU2018314228A1 (en) 2020-03-05

Similar Documents

Publication Publication Date Title
MY186217A (en) Mixture of hmos
SA520411910B1 (ar) تركيبات وطرق لعلاج اضطرابات مناعية باستخدام سلالات بكتيرية من المكورات اللبنية المعدلة للمناعة
PH12017501342A1 (en) Glycan therapeutics and related methods thereof
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2022000056A (es) Peptidos anti-microbianos estabilizados.
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2018000870A (es) Metodos y materiales para mejorar las respuestas inmunitarias y funciones de la barrera de piel y/o mucosa.
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
WO2016183532A8 (en) Bacteria engineered to treat a disease or disorder
CL2019002640A1 (es) Moléculas propioticas para reducir virulencia de patógenos.
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
MX2021016034A (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella.
WO2017139697A8 (en) Bacteria engineered to treat diseases associated with hyperammonemia
WO2016210384A3 (en) Bacteria engineered to treat metabolic diseases
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia
CN107405369A8 (zh) 包含细菌的组合物及将其用于治疗和/或预防胃肠道疾病、代谢疾病和/或其它疾病的方法
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
MX2019002924A (es) Composiciones purificadas de oligosacaridos de leche humana.
WO2017200873A8 (en) COMPOSITIONS AND METHODS FOR TREATING ACNE
PH12019550265A1 (en) Composition comprising mannose oligosaccharide and process for making same and use thereof
PH12018550110A1 (en) Novel probiotic bacterial strain of lactobacillus plantarum and compositions and uses thereof in the treatment of inflammation
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
WO2017123610A3 (en) Bacteria engineered to detoxify deleterious molecules
PH12019550183A1 (en) Treatment of infant colic